Soligenix signs technology licensing pact with CU
Soligenix is developing stabilization technology under an option-to-license agreement from CU, which was executed to provide support $9.4m National Institute of Allergy and Infectious Diseases (NIAID) grant for
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.